Risk
INSIGHT: Climate change, 23 May, 2023
How climate change alters the financial landscape
To achieve sustainability, companies and boards will need to look not only to their operations, but also to their finances.
NEWS: Board diversity, 4 May, 2023
Board appointments fell sharply in 2022
Companies appear to be sticking with experienced leaders—to the detriment of progress—suggests FTSE 350 boardroom research.
NEWS: Cyber security, 18 April, 2023
Cyber criminals chase ransomware insurance money
Specialist ransomware criminals are investigating victims’ insurance capacity—sometimes by blatantly asking companies outright.
NEWS: Investor relations, 13 April, 2023
Can dual-class shares help to curb greenhouse gases?
Extra voting rights could give the boost needed for firms to take higher risk ESG decisions on low-carbon technology, argues legal academic.
NEWS: Resilience reporting, 30 March, 2023
Resilience reports will involve ‘difficult decisions’
New government requirements mean boards will need to disclose planned responses to risks—leading to tough choices, a recent briefing heard.
NEWS: Net zero plans, 28 March, 2023
Investors seek commitment to net zero planning
Climate change campaigning investors have written to 107 companies, asking for prompt proof of net zero transition proposals.
INSIGHT: Risk management, 28 March, 2023
When employees become the competition
How might you be affected by a global move towards the banning of employment contract non-compete clauses?
NEWS: Ethics, 21 March, 2023
Call for FTSE 100 companies to give guidance on ethics
Most top firms have a published code of ethics, but many lack the framework to help their employees make ethical decisions, research finds.
NEWS: Investment risk, 20 March, 2023
Larry Fink puts focus on finance and inflation
Although BlackRock’s CEO does not mention the term ‘ESG’ in his annual letter, he highlights the investment risks posed by climate change.
NEWS: Life sciences podcast, 15 March, 2023
Reform of NHS levy ‘harms UK competitiveness’
Boards in the pharmaceutical and life sciences sector face increasingly difficult decisions, according to a recent Board Agenda podcast.